Homologous Recombination Deficiency Clinical Trials

6 recruiting

Homologous Recombination Deficiency Trials at a Glance

7 actively recruiting trials for homologous recombination deficiency are listed on ClinicalTrialsFinder across 6 cities in 6 countries. The largest study group is Phase 2 with 5 trials, with the heaviest enrollment activity in Houston, Nashville, and Barcelona. Lead sponsors running homologous recombination deficiency studies include Duke Street Bio Ltd, Eisbach Bio GmbH, and AtlasMedx, Incorporated.

Browse homologous recombination deficiency trials by phase

Treatments under study

About Homologous Recombination Deficiency Clinical Trials

Looking for clinical trials for Homologous Recombination Deficiency? There are currently 6 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Homologous Recombination Deficiency trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Homologous Recombination Deficiency clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 17 of 7 trials

Recruiting
Phase 2

Bipolar Androgen Therapy + Carboplatin in mCRPC

Homologous Recombination DeficiencyCastration-resistant Prostate Cancer
St Vincent's Hospital, Sydney30 enrolled1 locationNCT03522064
Recruiting
Phase 1

Study to Assess Safety, Tolerability and Activity of DSB2455 in Participants With Advanced Malignancies

Advanced Malignancies With Homologous Recombination Deficiency (HRD) (Breast, Ovarian, mCRPC, Brain Metastases)
Duke Street Bio Ltd90 enrolled13 locationsNCT06458712
Recruiting
Phase 1

Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors

Breast CancerOvarian CancerProstate Cancer+4 more
MOMA Therapeutics220 enrolled18 locationsNCT06545942
Recruiting
Phase 2Phase 3

Cisplatin to Patients With Pancreatic Cancer and Homologous Recombination Deficiency

Pancreatic AdenocarcinomaHomologous Recombination Deficiency
Fudan University30 enrolled1 locationNCT06095141
Recruiting
Phase 2

Olaparib in Patients With HRD Malignant Mesothelioma

Homologous Recombination DeficiencyMesothelioma
University of Chicago56 enrolled1 locationNCT04515836
Recruiting
Phase 1Phase 2

A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies

Breast CancerPancreatic CancerOvarian Cancer+3 more
AtlasMedx, Incorporated122 enrolled4 locationsNCT04503265
Recruiting
Phase 1Phase 2

EIS-12656 as Single Agent and in Combination in Patients With Specified Solid Tumors

Advanced Solid TumorHRR DeficiencyHomologous Recombination Deficiency
Eisbach Bio GmbH144 enrolled1 locationNCT06525298